Back to Journals » OncoTargets and Therapy » Volume 11

miR-517a promotes Warburg effect in HCC by directly targeting FBP1

Authors Zhang D, Li Z, Li T, Luo D, Feng X, Liu Y, Huang J

Received 24 April 2018

Accepted for publication 9 August 2018

Published 13 November 2018 Volume 2018:11 Pages 8025—8032

DOI https://doi.org/10.2147/OTT.S172084

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Giandomenico Roviello

Peer reviewer comments 3

Editor who approved publication: Dr Jianmin Xu


Delin Zhang,1,* Zhu Li,2,* Tao Li,1 Dan Luo,1 Xinfu Feng,1 Yan Liu,1 Jianzhao Huang1

1
Department of Hepatobiliary Surgery, Guizhou People’s Hospital, Guiyang 550002, China; 2Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550002, China

*These authors contributed equally to this work

Purpose: Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide. Our aim is to explore the expression and biological function of miR-517a in HCC.
Materials and methods: We performed qRT-PCR to detect the expression of miR-517a in clinical samples and cell lines. CKK-8 assay and colony formation assay were employed to detect the miR-517a regulated cell proliferation. Glucose uptake and lactate production were examined to determine the Warburg effect. We also performed ECAR assay using Seahorse system. Luciferase acitivy assay was used to examine the binding of FBP1 3’UTR by miR-517a.
Results: miR-517a was upregulated in HCC samples in both genomic and mRNA levels. Moreover, overexpression of miR-517a promoted cell proliferation and Warburg effect. Mechanically, miR-517a could directly target the 3′-UTR of FBP1. In addition, restoring the expression of FBP1 inhibited cell growth.
Conclusion: We demonstrated that miR-517a acts as an oncogene to promote Warburg effect in HCC, favoring tumor growth, and miR-517a/FBP1 could be a novel target for HCC treatment.

Keywords:
miR-517a, HCC, FBP1, Warburg effect

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]